{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:10Z","timestamp":1786986850004,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clinre.2022.101970","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:18:46Z","timestamp":1654085926000},"page":"101970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Yousaf","family":"Zafar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-1540","authenticated-orcid":false,"given":"Ahmed Mustafa","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Kamal","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayat","family":"Ellahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0364-6475","authenticated-orcid":false,"given":"Aymen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0464-0887","authenticated-orcid":false,"given":"Hassan ul","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furqan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh G.","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Jamal","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Talha","family":"Maniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2022.101970_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2022.101970_bib0002","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","article-title":"Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"65","author":"Brown","year":"2016","journal-title":"Metabolism"},{"issue":"16","key":"10.1016\/j.clinre.2022.101970_bib0003","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","author":"Benedict","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinre.2022.101970_bib0004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.clinre.2022.101970_bib0005","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.clinre.2022.101970_bib0006","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.clinre.2022.101970_bib0007","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.clinre.2022.101970_bib0008","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00592-018-1266-0","article-title":"A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?","volume":"56","author":"Lonardo","year":"2019","journal-title":"Acta Diabetol"},{"issue":"6","key":"10.1016\/j.clinre.2022.101970_bib0009","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.clinre.2022.101970_bib0010","doi-asserted-by":"crossref","first-page":"7356","DOI":"10.3748\/wjg.v20.i23.7356","article-title":"Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease","volume":"20","author":"Blaslov","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2022.101970_bib0011","unstructured":"Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Qiang S., Nakatsu Y., Seno Y., Fujishiro M., Sakoda H., Kushiyama A., Mori K., Matsunaga Y., Yamamotoya T., Kamata H., Asano T Diabetol. 2022"},{"key":"10.1016\/j.clinre.2022.101970_bib0012","doi-asserted-by":"crossref","unstructured":"Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. CarboneLJ, AngusPW, YeomansND J Gastroenterol Hepatol. 2016 31(1):23\u201331.","DOI":"10.1111\/jgh.13026"},{"issue":"1","key":"10.1016\/j.clinre.2022.101970_bib0013","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4239\/wjd.v12.i1.84","article-title":"Novel glucose-lowering drugs for non-alcoholic fatty liver disease","volume":"12","author":"Fu","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1016\/j.clinre.2022.101970_bib0014","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2022.101970_bib0015","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2009"},{"key":"10.1016\/j.clinre.2022.101970_bib0016","doi-asserted-by":"crossref","unstructured":"DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986 and 88., 7(3):177-.","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"10.1016\/j.clinre.2022.101970_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105319","article-title":"Simental-Mend\u00eda, Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials","volume":"163","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.clinre.2022.101970_bib0018","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4239\/wjd.v12.i1.84","article-title":"Novel glucose-lowering drugs for non-alcoholic fatty liver disease","volume":"12","author":"Fu","year":"2021","journal-title":"World J Diabetes"},{"issue":"5","key":"10.1016\/j.clinre.2022.101970_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.13237","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinre.2022.101970_bib0020","article-title":"Comparison of the efficacy of glucagon-like peptide-1 receptor agonists in patients with metabolic associated fatty liver disease: updated systematic review and meta-analysis","volume":"11","author":"Dai","year":"2021"},{"key":"10.1016\/j.clinre.2022.101970_bib0021","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.clinre.2022.101970_bib0022","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2022.101970_bib0023","unstructured":"Ferrannini E., Baldi S., Frascerra S., Astiarraga B., Heise T., Bizzotto R., Mari A., Pieber T.R., Muscelli E. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabe. 2022"},{"key":"10.1016\/j.clinre.2022.101970_bib0024","unstructured":"Vilar Gomez E., Rodriguez De Miranda A., Gra Oramas B., Arus Soler E., Llanio Navarro R., Calzadilla Bertot L., Yasells Garcia A., Del Rosario Abreu Vazquez M. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients wi. 2022"},{"key":"10.1016\/j.clinre.2022.101970_bib0025","article-title":"Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes","volume":"20","author":"Sanyal","year":"2022","journal-title":"Indian J Endocrinol Metab"},{"issue":"40","key":"10.1016\/j.clinre.2022.101970_bib0026","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.3748\/wjg.v20.i40.14821","article-title":"Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation","volume":"20","author":"Wang","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2022.101970_bib0027","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2022.101970_bib0028","unstructured":"Miyazaki M., Kato M., Tanaka K., Tanaka M., Kohjima M., Nakamura K., Enjoji M., Nakamuta M., Kotoh K., Takayanagi R. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose."},{"issue":"2","key":"10.1016\/j.clinre.2022.101970_bib0029","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0168-8278(97)80180-8","article-title":"Aberrant dipeptidyl peptidase IV (DPP IV\/CD26) expression in human hepatocellular carcinoma","volume":"27","author":"Stecca","year":"1997","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2022.101970_bib0030","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.2337\/db14-0052","article-title":"Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors","volume":"63","author":"Omar","year":"2014","journal-title":"Diabetes"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:27Z","timestamp":1761895947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122001048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2210740122001048"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.101970","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.101970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101970"}}